VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (6669)	5/18/1999 12:51:00 PM
From: scaram(o)uche	Read Replies (3) of 9719

>> CLTR faces a very tough, uphill battle to push aside rituxan before IDEC's next generation comes out. << We'll see. There are two outstanding trial results, apart from those with Idec's conjugate, that could push opinion one way or the other, violently. The CHOP study will be long and needs to be highly-powered, but we still need to know if tickling CD20 makes a cell more susceptible to routine chemo. Anyone know of an update or if IDPH's silence on this subject reflects some basic biology that has gone over my head? The naked antibody trial from CLTR..... it really upsets me that, after all this time, we hear that it will be a part of the NDA. Another competitor, Pretarget...... does anyone know if Rituxan was the antibody used for these preliminary results?...... biz.yahoo.com "This has allowed us to treat seven patients at radiation dose levels that some of them probably could not have tolerated otherwise. Substantial tumor regressions have occurred in most of these patients including documented complete responses."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next